SOURCE: INSYS Therapeutics

Insys Therapeutics

June 10, 2014 16:43 ET

Insys Therapeutics to Present at 9th Annual JMP Securities Healthcare Conference

PHOENIX, AZ--(Marketwired - Jun 10, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the company will present at the 9th Annual JMP Securities Healthcare Conference on June 24-25, 2014 at the Westin New York Grand Central.

Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will host the presentation on Wednesday, June 25, 2014 at 11:30 am EDT.

To listen to the live audio webcast of this presentation during the event, please visit: A replay of this webcast will be available for 30 days after the initial presentation.

About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative products for supportive care of cancer and pain patients. Using its proprietary sublingual spray technology and its capability to develop pharmaceutical cannabinoids, the company addresses the clinical shortcomings of existing commercial products. The company currently markets two products, Subsys, which is sublingual Fentanyl spray for break through cancer pain, and a generic version of Dronabinol (THC) capsules. The company plans to file a New Drug Application (NDA) for an oral liquid formulation of Dronabinol in the second half of 2014 and believes it is a clinically superior product to current Dronabinol capsules. The company is developing a robust pipeline of sublingual sprays, as well as pharmaceutical CBD.

Contact Information